8 Comments
 

Cantor Fitzgerald, while not typically ranked alongside the bulge bracket firms, holds a respectable position in the healthcare investment banking sector. Here are some insights and considerations regarding exit opportunities from Cantor's healthcare group:

  1. Industry Perception: Cantor is generally well-regarded in the healthcare investment banking space. While it may not carry the same prestige as some larger firms, it has a solid presence and can be a good platform for further career moves.

  2. Exit Opportunities: Analysts from Cantor's healthcare group can transition to various roles in the industry. Given your interest in a "pod shop" focusing on biotech, your experience at Cantor could indeed be valuable. Firms that specialize in biotech investments often value candidates with direct sector experience.

  3. Moving to BBER: Transitioning to a firm like BBER (assuming it represents a biotech-focused investment firm or hedge fund) would depend on several factors including your network, the relevance of your transactions and deals at Cantor, and how well you can market your sector-specific knowledge during the recruitment process.

  4. Networking and Skill Development: To enhance your chances of moving to a specialized biotech investment role, focus on building a strong network within the biotech investment community and continue developing your analytical skills, particularly those that are relevant to biotech valuations and transactions.

  5. Leveraging Cantor’s Deals: If you've been involved in significant deals at Cantor, particularly those related to biotech, these can be great talking points in interviews and can help bolster your application by demonstrating relevant experience and success in the field.

In summary, while Cantor may not have the brand power of some larger firms in every respect, its healthcare group can provide a solid foundation for moving into specialized investment roles, including those in biotech-focused funds.

Sources: HF to PE post-MBA - my story and seeking advice (long-time poster)!, Can we start a thread on the pros and cons of different coverage groups from a work / career perspective?, IB Christian SA in need of advice, AM vs HF: The Business of Our Business, Cap intro Q&A

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

Sequi voluptate veniam perspiciatis nostrum exercitationem dolores. Assumenda nesciunt nam ea et. Voluptate consequatur facilis vero rerum velit. Rerum ut occaecati pariatur sapiente odit aut.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
CompBanker's picture
CompBanker
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
DrApeman's picture
DrApeman
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”